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1. Introduction 
Stroke is the second most common cause of death and a major cause of serious long-term 
disability in adults in industrialized countries. Approximately 90% of strokes are ischemic 
and the rest are hemorrhagic.[1] Unfortunately, few effective treatments can be offered 
during the acute and subacute phases. Since the introduction of tissue plasminogen 
activator (tPA) in 1995, there are no other medical treatments for ischemic stroke besides the 
use of antiplatelets for primary and secondary prevention. Moreover, the clinical treatments 
for hemorrhagic stroke are also limited.  
In ischemic stroke most of therapies aim to recanalize the vessel and restore flow through 
pharmacological or endovascular treatments. However, another approach to preserve brain 
tissue is through the interruption of catalytic pathways triggered by ischemia. Rapid 
restoration of oxygen and glucose by thrombolysis will always provide the most effective 
neuroprotection, but directly targeting the brain parenchyma to confer neuroprotection may 
be a viable alternative, particularly in conjunction with thrombolysis. Multiple 
pharmacological attempts have failed in finding an ideal neuroprotective agent. Over 1000 
neuroprotective agents have been tested in basic stroke studies with many showing 
promise.[2] However, to date no neuroprotective agent has successfully transitioned from 
bench or animal studies into clinical use. Although cooling may be unable to salvage neural 
tissue that has irreversibly progressed to infarction, hypothermia minimizes the extent of 
secondary injury as an acute or subacute treatment strategy. Hypothermia is increasingly 
being used, especially since therapeutic mild hypothermia has demonstrated to positively 
influence neurological outcome in humans following acute brain injuries, namely, global 
ischemic brain injury due to cardiac arrest and hypoxic-ischemic encephalopathy in 
neonates.[3, 4]  
Catalytic cascades are generated in the brain tissue surrounding a blood clot after 
intracerebral hemorrhage (ICH). Hypothermia may also be used as a neuroprotection 
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treatment in these circumstances. Hypothermia has the potential to minimize secondary 
injury resulting from insufficient cerebral perfusion pressure or mechanical compression 
from herniation by ICH. Hypothermia preserves autoregulation of the cerebral vasculature 
and reduces cytotoxic edema around the hemorrhagic clot.[5]  
2. Pathophysiology of ischemic brain injury  
Ischemic brain injury is composed by the initial ischemic cascade and reperfusion 
injury.[6] During cerebral ischemia, cessation of blood flow and hypoxia trigger a complex set 
of metabolic and biochemical processes that comprise the ischemic cascade. An initial event in 
the ischemic cascade is the depletion of adenosine triphosphate (ATP), which is generated by 
oxygen-dependent phosphorylation in the central nervous system. ATP depletion leads to 
neurolemma depolarization secondary to derangement of Na+ and K+ gradients and, 
consequently, inappropriate accumulation of intracellular Ca2+ resulting from both Ca2+ influx 
and release from intracellular Ca2+ stores.[7] Increased intracellular Ca2+ concentration causes 
promiscuous activation of multiple intracellular enzyme systems, including protein kinase C, 
protein kinase B, calcium/calmodulin-dependent protein kinase II, mitogen-activated protein 
kinases, and phospholipases A2, C, and D. Prolonged elevations in intracellular 
Ca2+ concentration trigger the release of neurotrasmitters, which couples with the activation of 
multiple enzyme systems, inevitably leading to necrotic cell death through membrane 
dissolution if ischemia continues. In dogs, when ischemic brain is reperfused within 3 to 12 
minutes, neuronal ATP production appears to recover rapidly, with replenishment of baseline 
cellular levels within 6 minutes.[8] However, after 30 minutes of ischemia, the replenishment 
of ATP to baseline levels takes significantly longer (~36 minutes).[9] Furthermore, even after 3 
hours of reperfusion after intracranial thrombus injection, brain ATP levels still may not return 
to baseline levels.[10] Therefore, timely reperfusion is paramount, and after reperfusion is 
established, the direct cytotoxic effects of the ischemic cascade likely continue for minutes to 
hours until cellular ATP levels recover sufficiently. 
3. Hypothermia at the cellular level  
Hypothermia is neuroprotective through several mechanisms. The effects of hypothermia 
include a wide range of biological processes which include decreasing excitatory amino acid 
release, reducing free radical formation, enhancing small ubiquitin-related modifier-related 
pathways, attenuating protein kinase C activity and slowing cellular metabolism.[11-13] 
Hypothermia has little effect on the core of infarcted tissue, but acts on tissue at risk in the 
penumbra by modulating different mechanisms that lead to cellular injury and death.[14] A 
marked reduction in the metabolic demand of penumbral tissue with induced hypothermia 
may prevent damage due to oxidative stress and energy failure. Cooling also results in 
reduced proteolysis and excitotoxic damage caused by glutamate toxicity, and reduction in 
neuronal calcium influx.[15, 16]  
For every 1 °C reduction in brain temperature, the cerebral metabolic rate decreases in 6%. 
[17] Under stress conditions, hypothermia decreases high energy organic phosphates losses, 
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slows the rates of metabolite consumption and lactic acid accumulation and reduces cerebral 
metabolic oxygen consumption, while improving glucose utilization.[11]  
Hypothermia not only protects the brain by reducing cerebral metabolism during conditions 
of reduced substrate and shift to anaerobic glycolysis. Hypothermia also suppresses the 
accumulation and release of glutamate.[18] ATP loss during ischemia leads to ions flowing 
down their concentration gradients, and eventual efflux of potassium and influx of sodium 
and calcium.[19] Calcium influxes lead to direct neurotoxicity as well as extracellular 
accumulation of glutamate, which are neurotoxic. Experimental studies have shown that 
mild to moderate hypothermia attenuates the initial and delayed rise of extracellular 
potassium and prevents intracellular calcium accumulation, thus leading to decreased 
glutamate efflux and finally neuroprotection.  
Numerous studies have shown that hypothermia reduces the generation of reactive oxygen 
species, decreases brain edema, and prevents blood-brain barrier breakdown.[18] One 
potential mechanism is that hypothermia inhibits matrix metalloproteinases and preserves 
basal lamina proteins after stroke.[20-22] Moreover, a clinical study of 10 patients with large 
strokes who underwent mild hypothermia demonstrated lower levels of matrix 
metalloproteinase than normothermic patients.[23] Serum metalloproteinases are a good 
marker of blood-brain barrier breakdown.[20]  
Hypothermia has been documented by numerous investigators to alter gene expression 
normally observed after brain ischemia. Whereas a majority of genes are downregulated by 
hypothermia, a number of genes are also upregulated. [24] Interestingly, many 
proinflammatory and proapoptotic genes tend to be downregulated.[25-27] Whereas those 
genes that contribute to cell survival seem to be upregulated. [28-32]  
Additionally, hypothermia has been shown to inhibit activation of the inflammatory 
transcription factor nuclear factor kappa B via temperature-dependent inhibition of its 
inhibitor protein’s kinase. Other studies indicate that hypothermia has antiapoptotic effects 
such as reduction of cytochrome C release, and inhibition of caspases and proapoptotic 
genes.[33-37] 
4. Cooling temperatures 
Therapeutic hypothermia is defined as an intentionally induced, controlled reduction of a 
patient’s core temperature below 36°C. Further classification includes mild (34°C–35.9°C), 
moderate (32°C–33.9°C), moderate/deep (30°C–31.9°C), and deep (< 30°C) hypothermia. [38] 
In general, hypothermia appears to be effective whether the brain is cooled to 33°C or 28°C, 
but temperatures on the lower end appeared to be most effective according to a recent meta-
analysis of the experimental literature.[39] However, lower temperatures are associated with 
a higher incidence of complications, require more sedation and sometimes even induction of 
paralysis accompanied by intubation and ventilatory support.  
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5. Hypothermia in ischemic stroke 
Body temperature is increased in 4% to 25 % of patients with acute ischemic stroke within 
the first six hours after symptom onset.[40] The pathophysiology of this increase in body 
temperature is not completely understood. Higher body temperature may be a natural 
consequence of brain infarction. However, animal studies have suggested that higher body 
temperatures may increase the damage induced by cerebral ischemia.[41] Observational 
studies in patients with acute stroke have established the influence of body temperature on 
the clinical outcome of stroke. For each 1 °C increase in body temperature, the relative risk 
of poor outcome worsens more than two times.[42] This association may be limited to the 
first 12 to 24 hours from stroke onset.[42] These studies therefore suggest that control of 
body temperature and fever prevention may improve functional outcome after stroke.  
In a systematic review of animal studies, therapeutic hypothermia reduced infarct size by 
44% (95% confidence interval 40 to 47%). The best results were obtained with lower 
temperatures (≤ 31 °C), when treatment was started before or at the onset of ischemia, and in 
temporary rather than permanent ischemia models. However, a reduction in infarct volume 
by about one third was also observed with temperature reduction to 35 °C, with initiation of 
treatment between 90 and 180 minutes, and in permanent ischemia models.[39] The effects 
of hypothermia on functional outcome were broadly similar.[39] This suggests that 
temperature-lowering therapy might be effective for large numbers of patients with 
ischemic stroke. 
6. Human studies of hypothermia in ischemic stroke 
Clinical studies of induced hypothermia were conducted on humans based on successful 
cerebral ischemia animal models. One of the first studies cooled 17 patients with stroke 
admitted within 12 hours from symptom onset (mean 3.25 hours) for 6 hours.[43] 
Hypothermia was induced (35.5° C) with cooling blankets and shivering was treated with 
meperidine. Mortality at 6 months after stroke was 12% in the hypothermia group versus 
23% in historical matched-controls. Unfortunately, no benefit in terms of outcome was 
observed. It has been suggested that a longer hypothermia duration of 48–72 h may be 
required to reduce the formation of cerebral edema which usually occurs during the first 72-
h after symptom onset.  
Another study by Keller and collaborators measured the cerebral blood flow (CBF) and 
cerebral metabolic rate of oxygen consumption (CMRO2) in six patients with middle cerebral 
artery (MCA) strokes treated with hypothermia.[44] Patients were intubated and cooled 
with cooling blankets for 48 to 96 hours. A total of 19 measurements of CBF and jugular bulb 
O2 saturation were performed. This preliminary study suggested that moderate 
hypothermia (33° C) seems to reduce CBF and CMRO2 in humans.  
A small study evaluated the feasibility of inducing and maintaining moderate hypothermia 
with the use of endovascular rather than surface cooling.[45] Six patients with severe acute 
ischemic stroke were treated with moderate hypothermia. The pace of cooling was 1.4 +/- 
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0.6º C/h, and target temperature was reached after 3 +/- 1 h (range, 2 to 4.5 h). During 
hypothermia, the maximal temperature observed was 33.4º C, and the minimal temperature 
was 32.2º C. Every patient developed pneumonia and hypotension. This small study 
demonstrated that induction and maintenance of hypothermia with an intravenous cooling 
device was feasible.  
Cooling for acute ischemic brain damage (COOL-AID), was one of the first studies to 
evaluate hypothermia in ischemic stroke after thrombolysis.[46] This was a 
nonrandomized study that used surface cooling to achieve a cooling temperature of 32 ± 
1°C for 12 to 72-h. To prevent shivering, all patients undergoing hypothermia were 
intubated, sedated, and pharmacologically paralyzed. The study demonstrated that 
hypothermia is technically feasible and safe for patients with acute ischemic strokes who 
are undergoing thrombolytic therapy. However, the study was too small (10 patients) to 
determine any solid conclusions.  
A later version of the same study, evaluated and intravascular cooling device in the 
treatment of stroke through the induction of hypothermia. The second COOL-AID was a 
randomized controlled study of 40 patients presenting within 12- h of symptom onset. 
Eighteen patients were cooled and 22 received standard medical management, which 
included thrombolysis in 13 patients. Shivering was suppressed using a forced-air warming 
blanket, buspirone and meperidine. Eight patients in the hypothermia group required 
intubation during their hospitalization, one patient was intubated during the maintenance 
phase of hypothermia and the other for various reasons not related to cooling. Most patients 
tolerated hypothermia, and clinical outcomes were similar in both groups although there 
was a trend of reduced lesion growth on diffusion-weighted imaging in the group treated 
with hypothermia.[47] Side effects included pneumonia, cardiac arrhythmia, and deep vein 
thrombosis. The main lessons from these two studies (COOL-AID one and two) were that 
mild hypothermia can be achieved in awake patients with the appropriate cooling and anti-
shivering protocols; and that endovascular cooling achieves target temperature faster than 
surface cooling.  
ICTuS is another nonrandomized clinical trial that cooled 18 acute stroke patients using an 
endovascular cooling device.[48] Patients were cooled within 12 hours of symptom onset. 
An anti-shivering regimen with buspirone and meperidine was administered 
prophylactically. Overall, patients tolerated cooling well and the incidence of cerebral 
hemorrhage did not increase among patients (n=5) who received intravenous (IV) tPA. This 
trial confirmed that endovascular cooling with a proactive anti-shivering regimen can be 
accomplished in awake stroke patients. A later brain CT analysis of patients who were 
effectively cooled (n=7) versus those who were not (n=11), suggested that endovascular 
hypothermia decreases acute post-ichemic cerebral edema. [49] At the end of the cooling 
and rewarming period (36–48 h), patients who were effectively cooled had significantly 
decreased cerebral edema compared to patients who were either ineffectively cooled or not 
cooled at all. The effect disappeared by 30 days, as might be expected given the natural 
course of post-infarction cerebral edema. 
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A follow-up randomized, controlled study of endovascular cooling in awake patients after 
stroke (ICTuS-L), studied hypothermia with thrombolysis in patients presenting with acute 
ischemic stroke < 6 h from symptom onset.[50] Twenty eight patients were randomized to 
receive hypothermia and 30 to normothermia. There were no differences in outcome or 
incidence of adverse events comparing patients who were treated with tPA and hypothermia 
with those who were not cooled. For safety concerns, endovascular hypothermia with 
placement of the femoral cooling catheter was not begun until 30 to 180 minutes after 
completion of the tPA infusion, delaying cooling. Pneumonia was more frequent after 
hypothermia, although the occurrence of pneumonia did not significantly affect outcome at 
90 days. The study used meperidine, oral buspirone, and surface skin warming to prevent 
shivering in awake patients. This study demonstrated the feasibility and preliminary safety of 
combining endovascular hypothermia after stroke with intravenous thrombolysis, similarly 
to what the COOL AID study demonstrated previously.[46] 
The experience in the use of hypothermia with thrombolysis is limited in stroke patients. In 
the first COOL-AID study that used surface cooling, 4 of 10 patients received intra-arterial 
thrombolysis, and 2 received IV therapy.[46] In the second study, 3 of 18 patients were 
treated with intra-arterial therapy, and 10 received IV thrombolysis.[47] One patient who 
was treated with hypothermia and intra-arterial thrombolysis experienced retroperitoneal 
hemorrhage.[47] In the ICTuS-L trial, the rate of ICH was similar among patients who 
received tPA with hypothermia and those treated with tPA alone.[51] 
Hypothermia has also been studied with other neuroprotective agents in the treatment of 
acute ischemic stroke. Twenty patients with acute ischemic stroke were treated with 
caffeinol (caffeine 8-9 mg/kg + ethanol 0.4 g/kg intravenously x 2 hours, started by 4 hours 
after symptom onset) and hypothermia (started by 5 hours and continued for 24 hours (33-
35º C), followed by 12 hours of rewarming).[52] IV tPA was given to 16 patients within 3 
hours of symptom onset. Meperidine and buspirone were used to suppress shivering. 
Cooling was successfully achieved in 16 patients via endovascular and surface approaches. 
All patients reached target temperature, on average within 2 hours and 30 minutes from 
induction and 6 hours and 21 minutes from symptom onset. Three patients died: one from 
symptomatic hemorrhage, one from malignant cerebral edema, and one from unrelated 
medical complications. No adverse events were attributed to caffeinol.  
A small study evaluated the use of ice-cold saline for the induction of mild hypothermia in 10 
patients with acute ischemic stroke.[53] Ice-cold saline at 4°C (25 mL/kg body weight) was 
administered one time to induce mild hypothermia. Patients received buspirone and 
meperidine to prevent and treat shivering. Tympanic temperature dropped significantly by a 
maximum of 1.6 ± 0.3°C at 52 ± 16 minutes after ice-cold saline was started. The procedure was 
well tolerated, however, hypothermia was not maintained after the infusion of ice-cold saline.  
7. Hypothermia and thrombolysis  
Theoretically, the combination of hypothermia with pharmacological thrombolysis to 
restore blood flow and provide neuroprotection is a very promising strategy. However, 
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many serine proteases are affected by temperature, and the activity of tPA may be reduced 
in hypothermia.[54] In vitro analysis shows that cooling to 30°C to 33°C decreases tPA 
activity by 2% to 4%.[55] Moreover, it has been reported that the response to tPA may be 
related to body temperature at stroke presentation.[56] Investigators studied 111 acute 
stroke patients given tPA and found that patients presenting with a higher body 
temperature were more likely to have a favorable outcome compared with patients 
presenting with lower body temperatures. The authors suggested that this surprising 
finding might be explained by the benefit of im proved clot lysis by tPA at higher 
temperatures compared with the potential neuroprotective benefit of lower body 
temperature. 
A recent analysis of 5586 patients with acute ischemic stroke (1980 patients received tPA) 
determined that tPA treatment effect was not associated with baseline temperature.[57] 
Point estimates showed benefit of tPA treatment across 35.5°C to 37.5°C but showed a 
negative trend >37.5°C. Temperature profiles did not influence tPA effectiveness over 72 
hours after stroke. 
8. Hypothermia in the treatment of large MCA strokes 
Hypothermia has also been evaluated in the treatment of cerebral edema after large MCA 
infarctions. Schwab and collaborators induced moderate hypothermia in 25 patients with 
large MCA strokes.[58] Hypothermia was induced within 14 ± 7 hours after stroke onset by 
external cooling with cooling blankets, cold infusions, and cold washing. Hypothermia at 
33°C body-core temperature was maintained for 48 to 72 hours, and intracranial pressure 
(ICP), cerebral perfusion pressure, and brain temperature were continuously monitored. 
Elevated ICP values were significantly reduced during hypothermia. Herniation caused by a 
secondary rise in ICP after rewarming was the cause of death in most patients. The most 
frequent complication of moderate hypothermia was pneumonia in 10 of the 25 patients 
[40%). Authors concluded that moderate hypothermia can help to control critically elevated 
ICP values in severe space-occupying edema after MCA stroke. This and a similar study by 
the same group were pivotal in demonstrating that hypothermia was safe and effective in 
the treatment of increased ICP after malignant MCA infarction.[59]  
A prospective study performed by the same group, induced hypothermia in 50 patients 
with cooling blankets as well as alcohol and ice bags within 22 ± 9 hours after stroke 
onset.[59] Hypothermia was maintained for 24 to 72 hours and passive rewarming 
performed over a mean duration of 17 hours. Time required for cooling to < 33°C varied 
from 3.5 to 11 hours. The most frequent complications of hypothermic therapy were 
thrombocytopenia (70%). Faster rewarming (< 16 hours) was associated with rebound 
increased ICP, and most deaths occurred during the rewarming period. Further data in 
MCA infarct patients suggests that controlled rewarming rates of ≤ 0.1 per hour allow for 
improved control of ICP when compared with patients in whom rewarming is achieved in 
an uncontrolled fashion.[60] 
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Georgiadis and collaborators compared hypothermia with hemicraniectomy in the 
treatment of more than 2/3 of the MCA infarction.[61] Seventeen patients underwent 
hemicraniectomy and 19 were treated with moderate hypothermia (33°C), which was 
induced with cooling blankets and endovascular devices. Hypothermia was induced for 71 ± 
21 hours (range, 24 - 116 hours), whereas duration of rewarming varied between 25 and 34 
hours. Prolongation of hypothermia >72 hours was always related to raised ICP during 
rewarming attempts. Mortality was 12% in the hemicraniectomy group and 47% in the 
hypothermia group; one patient treated with hypothermia died as a result of cooling 
complications (sepsis) and three patients died of ICP crises that occurred during rewarming. 
Another small prospective study with 25 patients compared hypothermia with 
hemicraniectomy and hemicraniectomy alone in the treatment of patients with large MCA 
strokes.[62] Hemicraniectomy was performed within 15 +/- 6 h after the ischemic event, 
followed by hypothermia. There were no severe side effects of hypothermia. Patients treated 
with hemicraniectomy plus moderate hypothermia had a tendency to better outcome after 6 
months when compared to patients treated with hemicraniectomy alone.  
9. Human studies of hypothermia in hemorrhagic stroke 
ICH accounts for approximately 10% of strokes and the 30-day mortality rate is 
approximately 52%.[63] After the acute phase of ICH, high morbidity and mortality are 
essentially caused by the evolution of a peri-hemorrhagic, space-occupying edema 
associated with gradually increasing ICP.[64] Although the natural course of edema 
formation is still not fully understood, edema mostly increases during the first week and 
reaches its maximum during the second week after bleeding onset.[65, 66] Animal studies 
have suggested that hypothermia may have a neuroprotective role after ICH in reducing 
edema formation by various mechanisms.[67, 68]  
One of the first experiences with hypothermia in the treatment of ICH was reported by 
Howell and collaborators in 1956.[69] Hypothermia between 30°C to 32°C was induced in 
eight patients with spontaneous ICH. Although signs of herniation improved in all patients, 
six patients died from systemic complications, most commonly aspiration. Anecdotally, 
hypothermia was induced with ice bags, alcohol, and even opening the windows in the 
middle of the Canadian winter.  
Kollmar and collaborators treated twelve patients with supratentorial large ICH (> 25 mL) 
with hypothermia (35°C) for 10 days.[5] In the hypothermia group, edema volume 
remained stable during 14 days, whereas edema significantly increased in the control 
group. However, pneumonia was more frequent in the hypothermia group. Based on 
these results, the same investigators planned the Cooling in Intracerebral Hemorrhage 
(CINCH) trial. [70] This is a prospective multicenter trial that WILL enroll 50 patients 
with large ICH and randomly assign them to mild hypothermia versus conventional 
medical management.  
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Kammersgaa
rd (43) (2000) 
Single center, 
nonrandomized, 
open label.  
17 12 h Surface 6 h Non-
intubated 
Meperidine 35.5°C 6 h Infection 18% Awake patients tolerated surface 
hypothermia. 
Keller (44) 
(2000) 
Single center, 
nonrandomized, 
open label.  
6 63.5 h Surface 48-96 h Intubated Midazolam, fentanyl 
and atracurium.  
33°C NA NA Hypothermia decreased CMRO2 
and CBF.  
Georgiadis 
(45) 
(2001) 
Single center, 
nonrandomized, 
open label.  
6 28±17 h Endovascular 48-72 h Intubated Midazolam, fentanyl 
and atracurium.  
33°C 3±1 h Bradycardia 50% 
Pneumonia 100% 
Hypotension 100% 
Thromb 33% 
Induction and maintenance of 
hypothermia with intravenous 
cooling was feasible.  
Krieger (46) 
(2001) 
Single center, 
nonrandomized, 
open label, 
parallel control 
(COOL AID) 
10 6 h Surface 12-72 h Intubated Propofol and 
atracurium. 
33°C  3.5± 
1.5 h 
Bradycardia 50% 
Arrythmia 30% 
Hypotension 30% 
Hypothermia was well tolerated 
after thrombolysis.  
De Georgia 
(47) 
(2004) 
Multicenter, 
randomized, 
open label.  
(COOL AID) 
18 12 h Endovascular 24 h Non-
intubated 
Air warming blanket, 
buspirone and 
meperidine. 
33°C 77±  
44 min 
Pneumonia 11% 
Arrythmia 11% 
Retroperitoneal  
hematoma 5% 
Endovascular hypothermia in 
awake patients was well 
tolerated.  
Lyden (48) 
(2005) 
Multicenter, 
open label, 
nonrandomized. 
(ICTuS) 
18 12 h Endovascular 12-24 h Non-
intubated 
Air warming blanket, 
buspirone and 
meperidine. 
33°C 7 h DVT 22% 
Bradycardia 22% 
Hypokalemia 22% 
Groin hematoma 
11% 
Arrythmia 11% 
Endovascular hypothermia in 
awake patients was well 
tolerated.  
Martin-
Schild (52) 
(2009) 
Single center, 
nonrandomized, 
open label.  
18 5 h Surface and 
endovascular 
24 h Non-
intubated 
Air warming blanket, 
buspirone and 
meperidine. 
33-35°C  8 h Pneumonia 20% Hypothermia was combined with 
caffeinol and tPA in nonintubated 
patients.  
Hemmen 
(50) 
(2010) 
Multicenter, 
randomized, 
double-blinded.  
(ICTuS-L) 
28 6 h Endovascular 24 h Non-
intubated 
Air warming blanket, 
buspirone and 
meperidine. 
33°C 7 h  Pneumonia 25% 
DVT 14% 
Hypothermia was well tolerated 
after thrombolysis. 24-h 
assessments were affected by 
sedation in the hypothermia 
group.  
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Schwab (58) 
(1998) 
Single center, 
nonrandomized, 
open label.  
25 14±7 h Surface  48-72 h Intubated Fentanyl, propofol 
and atracurium. 
33°C 14±4 h Pneumonia 10% 
Arrythmia 60% 
Hypothermia effective in the 
treatment of increased ICP after 
MCA infarction.  
Schwab (59) 
(1998) 
Single center, 
nonrandomized, 
open label.  
50 22±9 h Surface 48-72 h Intubated Fentanyl, midazolam 
or propofol and 
atracurium. 
33°C 22 ± 3.5 - 
11 h 
Thromb 70% 
Bradycardia 62% 
Pneumonia 48% 
Fast rewarming was associated 
with rebound increased ICP.  
Georgiadis 
(61) 
(2002) 
Single center, 
nonrandomized, 
open label.  
19 24 h Surface and 
endovascular 
48-72 h Intubated Fentanyl, midazolam 
and atracurium. 
33°C 4 ± 1 h Pneumonia 78% 
Arrythmia 42% 
Bradycardia 58% 
Thromb 37% 
Hypokalemia 26% 
Hypothermia was compared with 
hemicraniectomy in the treatment 
of large MCA strokes. The 
hypothermia group had higher 
mortality due to increased ICP 
during rewarming.  
Els (62) 
(2006) 
Single center, 
randomized, 
open label.  
12 NA Surface and 
endovascular 
48 h Intubated Fentanyl and 
midazolam. 
35°C 2 ± 1 h Bradycardia 8% Hypothermia was used with 
hemicraniectomy. 
H
e
m
o
r
r
h
a
g
i
c
 
S
t
r
o
k
e
 Kollmar (70) 
(2010) 
Single center, 
nonrandomized, 
open label.  
12 12 h Endovascular 10 d Intubated Sufentanyl, 
midazolam, 
meperidine and 
cisatracurium 
35°C NA Pneumonia 100% 
Thromb 33% 
Bradycardia 25% 
Hypothermia decreased 
perihematomal edema.  
Temp = temperature; thromb = thrombocytopenia; CMRO2 = Cerebral metabolic rate of oxigen; CBF = cerebral blood flow; tPA = tissue plasminogen activator; ICP = intracranial pressure; MCA = middle 
cerebral artery; NA = not available; h = hour, d = day; min = minutes. 
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Hypothermia has also been evaluated in the management of subarachnoid hemorrhage 
(SAH). Gasser and collaborators treated 21 patients with poor grade SAH and cerebral 
edema with long-term hypothermia (>72 hrs).[71] Nine patients were treated for <72 hrs and 
12 for >72 hrs. Functional independence at 3 months was achieved in 48% of patients, but 
the outcome did not differ with the group of patients treated without hypothermia. The 
most common form of complication was infection in both groups.  
10. Complications of hypothermia 
Induced therapeutic hypothermia is an intensive care procedure that has to be performed 
under continuous monitoring. Since most patients who are cooled are critically ill, they may 
be more prone to develop complications. These complications appear to be associated with 
de degree of hypothermia, with the risk of side effects being correlated with prolonged 
hypothermia and lower temperatures. In general, hypothermia is well tolerated, but 
complications may include: 1) cardiac: arrhythmias, bradycardia, reduced ventricular 
contractility, and hypotension; 2) immunologic: immunosuppression; 3) hematologic: 
thrombocytopenia and mild coagulopathy; and 4) metabolic: shivering, hyperglycemia, 
hypokalemia, ileus, and cold-induced diuresis. The most common complication in reported 
studies is pneumonia, followed by asymptomatic bradycardia, cardiac arrhythmias and 
thrombocytopenia (table).[14] 
Pneumonia appears to occur more frequently in intubated patients who undergo cooling. 
Endovascular cooling with use of warm blankets to reduce shivering and prevent intubation 
is an alternative to surface cooling and may reduce the rate of pneumonia.  
The most dangerous phase of induced hypothermia is the rewarming period. Particular care 
is required in stroke patients with intracranial mass effect and elevated ICP. Overly rapid 
rewarming can lead to a systemic inflammatory response syndrome; with systemic 
vasodilatation, hypotension, and reflex ICP elevation.[14] As a general rule, hypothermia 
patients with increased ICP should undergo active controlled rewarming (or “decooling”) at 
a rate of 0.1°C per hour. Faster rates of 0.25°C to 0.33°C per hour can be tolerated in patients 
without ICP issues.[72-74] This high ICP rebound has especially been observed in patients 
with malignant MCA infarctions.[75] 
One common complication of hypothermia that usually is overlooked is sedation. It has 
been demonstrated that patients who undergo hypothermia are more likely to receive 
sedation than those who are not treated with hypothermia.[76] Sedation in hypothermia 
patients may linger longer in the system, confounding neurological examination and 
prognostication.[77] This becomes a relevant issue in stroke patients who require daily 
neurological assessments.  
11. Conclusion and recommendations 
Despite the many potential neuroprotective effects of hypothermia seen in animal stroke 
models and the benefit of hypothermia observed in humans following cardiac arrest, there is 
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still no solid evidence demonstrating improved outcomes in stroke patients. In addition, a 
systematic review found no definitive evidence that either physical or chemical cooling 
interventions improve outcomes after acute ischemic stroke.[78] The total number of 
participants included in the studies reviewed in this chapter is far to small and the 
interventions too heterogeneous for definitive conclusions (table). Moreover, all studies 
were designed to test safety and feasibility, and allowed rather long time periods between 
stroke onset and start of cooling, which may lower the likelihood of observing a treatment 
effect.  
Stroke studies have used surface and endovascular cooling systems for induction and 
maintenance of hypothermia (table). Goal temperatures usually range from 33° to 35°C. IV 
infusion of ice-cold saline [25 mL/kg body weight) has been shown to induce hypothermia 
rapidly and may be used as an initial cooling method in stroke patients who are initially 
assessed in the field.[53]  
Pharmacologic agents like meperidine and buspirone, and concurrent skin warming inhibit 
shivering and allow patients to tolerate treatment with less sedation. Moreover, these anti-
shivering protocols have allowed the induction and maintenance of mild and moderate 
hypothermia in awake patients.[47] Recent studies have demonstrated that endovascular 
cooling is more accurate in keeping patients in the target temperature range than surface 
cooling with ice bags and cooling blankets.[79, 80] Endovascular cooling also allows for 
concurrent use of surface warming to reduce shivering. However, endovascular cooling 
implies accessing the femoral vein to place the cooling catheter, increasing the risk of 
procedural complications and infection. In general, each center should choose the cooling 
method that is more familiar to the personnel and easier to implement.  
Similar uncertainty exists on the optimal treatment duration. In animal models of focal 
cerebral ischemia, pathophysiological processes exert their deleterious effects over various 
time courses, extending from the first hours to several days after vessel occlusion.[81] Such 
observations may imply that temperature lowering therapy should be more effective when 
used for prolonged time. On the other hand, longer treatment was not associated with 
improved outcomes in a meta-analysis of hypothermia in animal models of focal cerebral 
ischemia. Moreover, the risk of side effects such as infections may increase with longer 
cooling times.[39] In clinical trials of cardiac arrest, hypothermia was maintained for 12 or 24 
hours.[3] Most recent studies of hypothermia in acute ischemic stroke aim for 12 – 24 hours 
of cooling (table).  
For unknown reasons, patients with massive brain injuries may experience rebound 
intracranial hypertension when rapidly rewarmed after prolonged periods of mild to 
moderate hypothermia. Whether this occurs in experimental stroke models has not been 
widely studied. Previous stroke studies suggest that controlled rewarming seems to prevent 
rebound brain edema and is the standard protocol in most recent trials.[14] Trials using 
milder hypothermia [35°C) and slower rewarming periods have reported lower 
complication rates.[62] For practical purposes, a 24-hour cooling period followed by a >12-
hour slow rewarming, such as 0.1° C/h is advised.[82] 
 
Therapeutic Hypothermia in Acute Stroke 63 
Author details 
Edgar A. Samaniego 
Baptist Neuroscience Center, Baptist Cardiac and Vascular Institute, Miami, Florida, USA  
12. References 
[1] Adams HP, Jr., Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. 
Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter 
clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993 
Jan;24(1):35-41. 
[2] O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 
1,026 experimental treatments in acute stroke. Ann Neurol. 2006 Mar;59(3):467-77. 
[3] Bernard SA, Gray TW, Buist MD, Jones BM, Silvester W, Gutteridge G, et al. Treatment 
of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N 
Engl J Med. 2002 Feb 21;346(8):557-63. 
[4] Gluckman PD, Wyatt JS, Azzopardi D, Ballard R, Edwards AD, Ferriero DM, et al. 
Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: 
multicentre randomised trial. Lancet. 2005 Feb 19-25;365(9460):663-70. 
[5] Kollmar R, Staykov D, D√∂rfler A, Schellinger PD, Schwab S, Bardutzky Jr. 
Hypothermia Reduces Perihemorrhagic Edema After Intracerebral Hemorrhage. Stroke. 
[10.1161/STROKEAHA.110.587758]. 2010;41(8):1684-9. 
[6] Hammer MD, Krieger DW. Hypothermia for acute ischemic stroke: not just another 
neuroprotectant. Neurologist. 2003 Nov;9(6):280-9. 
[7] Lee JM, Grabb MC, Zipfel GJ, Choi DW. Brain tissue responses to ischemia. J Clin 
Invest. 2000 Sep;106(6):723-31. 
[8] Nishijima MK, Koehler RC, Hurn PD, Eleff SM, Norris S, Jacobus WE, et al. 
Postischemic recovery rate of cerebral ATP, phosphocreatine, pH, and evoked 
potentials. Am J Physiol. 1989 Dec;257(6 Pt 2):H1860-70. 
[9] Kintner D, Costello DJ, Levin AB, Gilboe DD. Brain metabolism after 30 minutes of 
hypoxic or anoxic perfusion or ischemia. Am J Physiol. 1980 Dec;239(6):E501-9. 
[10] Busch E, Kruger K, Allegrini PR, Kerskens CM, Gyngell ML, Hoehn-Berlage M, et al. 
Reperfusion after thrombolytic therapy of embolic stroke in the rat: magnetic resonance 
and biochemical imaging. J Cereb Blood Flow Metab. 1998 Apr;18(4):407-18. 
[11] Yenari MA, Colbourne F, Hemmen TM, Han HS, Krieger D. Therapeutic hypothermia 
in stroke. Stroke Res Treat. 2011;2011:157969. 
[12] Berger C, Schabitz WR, Georgiadis D, Steiner T, Aschoff A, Schwab S. Effects of 
hypothermia on excitatory amino acids and metabolism in stroke patients: a 
microdialysis study. Stroke. 2002 Feb;33(2):519-24. 
[13] Globus MY, Alonso O, Dietrich WD, Busto R, Ginsberg MD. Glutamate release and free 
radical production following brain injury: effects of posttraumatic hypothermia. J 
Neurochem. 1995 Oct;65(4):1704-11. 
 Therapeutic Hypothermia in Brain Injury 64 
[14] Linares G, Mayer SA. Hypothermia for the treatment of ischemic and hemorrhagic 
stroke. Crit Care Med. 2009 Jul;37(7 Suppl):S243-9. 
[15] Ji X, Luo Y, Ling F, Stetler RA, Lan J, Cao G, et al. Mild hypothermia diminishes 
oxidative DNA damage and pro-death signaling events after cerebral ischemia: a 
mechanism for neuroprotection. Front Biosci. 2007;12:1737-47. 
[16] Feigin VL, Anderson CS, Rodgers A, Anderson NE, Gunn AJ. The emerging role of 
induced hypothermia in the management of acute stroke. J Clin Neurosci. 2002 
Sep;9(5):502-7. 
[17] Steen PA, Newberg L, Milde JH, Michenfelder JD. Hypothermia and barbiturates: 
individual and combined effects on canine cerebral oxygen consumption. 
Anesthesiology. 1983 Jun;58(6):527-32. 
[18] Liu L, Yenari MA. Therapeutic hypothermia: neuroprotective mechanisms. Front Biosci. 
2007;12:816-25. 
[19] Yenari M, Kitagawa K, Lyden P, Perez-Pinzon M. Metabolic downregulation: a key to 
successful neuroprotection? Stroke. 2008 Oct;39(10):2910-7. 
[20] Wagner S, Nagel S, Kluge B, Schwab S, Heiland S, Koziol J, et al. Topographically 
graded postischemic presence of metalloproteinases is inhibited by hypothermia. Brain 
Res. 2003 Sep 12;984(1-2):63-75. 
[21] Hamann GF, Burggraf D, Martens HK, Liebetrau M, Jager G, Wunderlich N, et al. Mild 
to moderate hypothermia prevents microvascular basal lamina antigen loss in 
experimental focal cerebral ischemia. Stroke. 2004 Mar;35(3):764-9. 
[22] Lee JE, Yoon YJ, Moseley ME, Yenari MA. Reduction in levels of matrix 
metalloproteinases and increased expression of tissue inhibitor of metalloproteinase-2 
in response to mild hypothermia therapy in experimental stroke. J Neurosurg. 2005 
Aug;103(2):289-97. 
[23] Horstmann S, Koziol JA, Martinez-Torres F, Nagel S, Gardner H, Wagner S. 
Sonographic monitoring of mass effect in stroke patients treated with hypothermia. 
Correlation with intracranial pressure and matrix metalloproteinase 2 and 9 expression. 
J Neurol Sci. 2009 Jan 15;276(1-2):75-8. 
[24] Ohta H, Terao Y, Shintani Y, Kiyota Y. Therapeutic time window of post-ischemic mild 
hypothermia and the gene expression associated with the neuroprotection in rat focal 
cerebral ischemia. Neurosci Res. 2007 Mar;57(3):424-33. 
[25] Han HS, Qiao Y, Karabiyikoglu M, Giffard RG, Yenari MA. Influence of mild 
hypothermia on inducible nitric oxide synthase expression and reactive nitrogen 
production in experimental stroke and inflammation. J Neurosci. 2002 May 
15;22(10):3921-8. 
[26] Xu L, Yenari MA, Steinberg GK, Giffard RG. Mild hypothermia reduces apoptosis of 
mouse neurons in vitro early in the cascade. J Cereb Blood Flow Metab. 2002 
Jan;22(1):21-8. 
[27] Van Hemelrijck A, Hachimi-Idrissi S, Sarre S, Ebinger G, Michotte Y. Post-ischaemic 
mild hypothermia inhibits apoptosis in the penumbral region by reducing neuronal 
nitric oxide synthase activity and thereby preventing endothelin-1-induced hydroxyl 
radical formation. Eur J Neurosci. 2005 Sep;22(6):1327-37. 
 
Therapeutic Hypothermia in Acute Stroke 65 
[28] Zhao H, Shimohata T, Wang JQ, Sun G, Schaal DW, Sapolsky RM, et al. Akt contributes 
to neuroprotection by hypothermia against cerebral ischemia in rats. J Neurosci. 2005 
Oct 19;25(42):9794-806. 
[29] D'Cruz BJ, Fertig KC, Filiano AJ, Hicks SD, DeFranco DB, Callaway CW. Hypothermic 
reperfusion after cardiac arrest augments brain-derived neurotrophic factor activation. J 
Cereb Blood Flow Metab. 2002 Jul;22(7):843-51. 
[30] Schmidt KM, Repine MJ, Hicks SD, DeFranco DB, Callaway CW. Regional changes in 
glial cell line-derived neurotrophic factor after cardiac arrest and hypothermia in rats. 
Neurosci Lett. 2004 Sep 23;368(2):135-9. 
[31] Boris-Moller F, Kamme F, Wieloch T. The effect of hypothermia on the expression of 
neurotrophin mRNA in the hippocampus following transient cerebral ischemia in the 
rat. Brain Res Mol Brain Res. 1998 Dec 10;63(1):163-73. 
[32] Vosler PS, Logue ES, Repine MJ, Callaway CW. Delayed hypothermia preferentially 
increases expression of brain-derived neurotrophic factor exon III in rat hippocampus 
after asphyxial cardiac arrest. Brain Res Mol Brain Res. 2005 Apr 27;135(1-2):21-9. 
[33] Zhao H, Yenari MA, Cheng D, Sapolsky RM, Steinberg GK. Biphasic cytochrome c 
release after transient global ischemia and its inhibition by hypothermia. J Cereb Blood 
Flow Metab. 2005 Sep;25(9):1119-29. 
[34] Zhang Z, Sobel RA, Cheng D, Steinberg GK, Yenari MA. Mild hypothermia increases 
Bcl-2 protein expression following global cerebral ischemia. Brain Res Mol Brain Res. 
2001 Nov 1;95(1-2):75-85. 
[35] Yenari MA, Iwayama S, Cheng D, Sun GH, Fujimura M, Morita-Fujimura Y, et al. Mild 
hypothermia attenuates cytochrome c release but does not alter Bcl-2 expression or 
caspase activation after experimental stroke. J Cereb Blood Flow Metab. 2002 
Jan;22(1):29-38. 
[36] Inamasu J, Suga S, Sato S, Horiguchi T, Akaji K, Mayanagi K, et al. Postischemic 
hypothermia attenuates apoptotic cell death in transient focal ischemia in rats. Acta 
Neurochir Suppl. 2000;76:525-7. 
[37] Prakasa Babu P, Yoshida Y, Su M, Segura M, Kawamura S, Yasui N. 
Immunohistochemical expression of Bcl-2, Bax and cytochrome c following focal 
cerebral ischemia and effect of hypothermia in rat. Neurosci Lett. 2000 Sep 
22;291(3):196-200. 
[38] Polderman KH, Herold I. Therapeutic hypothermia and controlled normothermia in the 
intensive care unit: practical considerations, side effects, and cooling methods. Crit Care 
Med. 2009 Mar;37(3):1101-20. 
[39] van der Worp HB, Sena ES, Donnan GA, Howells DW, Macleod MR. Hypothermia in 
animal models of acute ischaemic stroke: a systematic review and meta-analysis. Brain. 
2007 Dec;130(Pt 12):3063-74. 
[40] Boysen G, Christensen H. Stroke severity determines body temperature in acute stroke. 
Stroke. 2001 Feb;32(2):413-7. 
[41] Chopp M, Welch KM, Tidwell CD, Knight R, Helpern JA. Effect of mild hyperthermia 
on recovery of metabolic function after global cerebral ischemia in cats. Stroke. 1988 
Dec;19(12):1521-5. 
 Therapeutic Hypothermia in Brain Injury 66 
[42] Reith J, Jorgensen HS, Pedersen PM, Nakayama H, Raaschou HO, Jeppesen LL, et al. 
Body temperature in acute stroke: relation to stroke severity, infarct size, mortality, and 
outcome. Lancet. 1996 Feb 17;347(8999):422-5. 
[43] Kammersgaard LP, Rasmussen BH, Jorgensen HS, Reith J, Weber U, Olsen TS. 
Feasibility and safety of inducing modest hypothermia in awake patients with acute 
stroke through surface cooling: A case-control study: the Copenhagen Stroke Study. 
Stroke. 2000 Sep;31(9):2251-6. 
[44] Keller E, Steiner T, Fandino J, Schwab S, Hacke W. Changes in cerebral blood flow and 
oxygen metabolism during moderate hypothermia in patients with severe middle 
cerebral artery infarction. Neurosurg Focus. 2000;8(5):e4. 
[45] Georgiadis D, Schwarz S, Kollmar R, Schwab S. Endovascular cooling for moderate 
hypothermia in patients with acute stroke: first results of a novel approach. Stroke. 2001 
Nov;32(11):2550-3. 
[46] Krieger DW, De Georgia MA, Abou-Chebl A, Andrefsky JC, Sila CA, Katzan IL, et al. 
Cooling for acute ischemic brain damage (cool aid): an open pilot study of induced 
hypothermia in acute ischemic stroke. Stroke. 2001 Aug;32(8):1847-54. 
[47] De Georgia MA, Krieger DW, Abou-Chebl A, Devlin TG, Jauss M, Davis SM, et al. 
Cooling for Acute Ischemic Brain Damage (COOL AID): a feasibility trial of 
endovascular cooling. Neurology. 2004 Jul 27;63(2):312-7. 
[48] Lyden PD, Allgren RL, Ng K, Akins P, Meyer B, Al-Sanani F, et al. Intravascular 
Cooling in the Treatment of Stroke (ICTuS): early clinical experience. J Stroke 
Cerebrovasc Dis. 2005 May-Jun;14(3):107-14. 
[49] Guluma KZ, Oh H, Yu SW, Meyer BC, Rapp K, Lyden PD. Effect of endovascular 
hypothermia on acute ischemic edema: morphometric analysis of the ICTuS trial. 
Neurocrit Care. 2008;8(1):42-7. 
[50] Hemmen TM, Raman R, Guluma KZ, Meyer BC, Gomes JA, Cruz-Flores S, et al. 
Intravenous thrombolysis plus hypothermia for acute treatment of ischemic stroke 
(ICTuS-L): final results. Stroke. 2010 Oct;41(10):2265-70. 
[51] Hemmen TM, Lyden PD. Induced Hypothermia for Acute Stroke. Stroke. 
[10.1161/01.STR.0000247920.15708.fa]. 2007;38(2):794-9. 
[52] Martin-Schild S, Hallevi H, Shaltoni H, Barreto AD, Gonzales NR, Aronowski J, et al. 
Combined neuroprotective modalities coupled with thrombolysis in acute ischemic 
stroke: a pilot study of caffeinol and mild hypothermia. Journal of Stroke and 
Cerebrovascular Diseases: The Official Journal of National Stroke Association. 
[10.1016/j.jstrokecerebrovasdis.2008.09.015]. 2009;18(2):86-96. 
[53] Kollmar R, Schellinger PD, Steigleder T, Kohrmann M, Schwab S. Ice-cold saline for the 
induction of mild hypothermia in patients with acute ischemic stroke: a pilot study. 
Stroke. 2009 May;40(5):1907-9. 
[54] Hemmen TM, Lyden PD. Induced hypothermia for acute stroke. Stroke. 2007 Feb;38(2 
Suppl):794-9. 
[55] Yenari MA, Palmer JT, Bracci PM, Steinberg GK. Thrombolysis with tissue plasminogen 
activator (tPA) is temperature dependent. Thromb Res. 1995 Mar 1;77(5):475-81. 
 
Therapeutic Hypothermia in Acute Stroke 67 
[56] Naess H, Idicula T, Lagallo N, Brogger J, Waje-Andreassen U, Thomassen L. Inverse 
relationship of baseline body temperature and outcome between ischemic stroke 
patients treated and not treated with thrombolysis: the Bergen stroke study. Acta 
Neurol Scand. 2010 Dec;122(6):414-7. 
[57] Lees JS, Mishra NK, Saini M, Lyden PD, Shuaib A. Low body temperature does not 
compromise the treatment effect of alteplase. Stroke. 2011 Sep;42(9):2618-21. 
[58] Schwab S, Schwarz S, Spranger M, Keller E, Bertram M, Hacke W. Moderate 
hypothermia in the treatment of patients with severe middle cerebral artery infarction. 
Stroke. 1998 Dec;29(12):2461-6. 
[59] Schwab S, Georgiadis D, Berrouschot Jr, Schellinger PD, Graffagnino C, Mayer SA. 
Feasibility and Safety of Moderate Hypothermia After Massive Hemispheric Infarction. 
Stroke. [10.1161/hs0901.095394]. 2001;32(9):2033-5. 
[60] Steiner T, Friede T, Aschoff A, Schellinger PD, Schwab S, Hacke W. Effect and 
feasibility of controlled rewarming after moderate hypothermia in stroke patients with 
malignant infarction of the middle cerebral artery. Stroke; a Journal of Cerebral 
Circulation. 2001;32(12):2833-5. 
[61] Georgiadis D, Schwarz S, Aschoff A, Schwab S. Hemicraniectomy and moderate 
hypothermia in patients with severe ischemic stroke. Stroke. 2002 Jun;33(6):1584-8. 
[62] Els T, Oehm E, Voigt S, Klisch J, Hetzel A, Kassubek J. Safety and therapeutical benefit 
of hemicraniectomy combined with mild hypothermia in comparison with 
hemicraniectomy alone in patients with malignant ischemic stroke. Cerebrovasc Dis. 
2006;21(1-2):79-85. 
[63] Broderick J, Connolly S, Feldmann E, Hanley D, Kase C, Krieger D, et al. Guidelines for 
the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a 
guideline from the American Heart Association/American Stroke Association Stroke 
Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes 
in Research Interdisciplinary Working Group. Circulation. 
[10.1161/CIRCULATIONAHA.107.183689]. 2007;116(16):e391-413-e391-413. 
[64] Zazulia AR, Diringer MN, Derdeyn CP, Powers WJ. Progression of mass effect after 
intracerebral hemorrhage. Stroke; a Journal of Cerebral Circulation. 1999;30(6):1167-73. 
[65] Inaji M, Tomita H, Tone O, Tamaki M, Suzuki R, Ohno K. Chronological changes of 
perihematomal edema of human intracerebral hematoma. Acta Neurochirurgica 
Supplement. 2003;86:445-8. 
[66] Venkatasubramanian C, Mlynash M, Finley-Caulfield A, Eyngorn I, Kalimuthu R, 
Snider RW, et al. Natural History of Perihematomal Edema After Intracerebral 
Hemorrhage Measured by Serial Magnetic Resonance Imaging. Stroke. 
[10.1161/STROKEAHA.110.590646]. 2011;42(1):73-80. 
[67] MacLellan CL, Davies LM, Fingas MS, Colbourne F. The influence of hypothermia on 
outcome after intracerebral hemorrhage in rats. Stroke; a Journal of Cerebral 
Circulation. [10.1161/01.STR.0000217268.81963.78]. 2006;37(5):1266-70. 
[68] Kawanishi M, Kawai N, Nakamura T, Luo C, Tamiya T, Nagao S. Effect of delayed mild 
brain hypothermia on edema formation after intracerebral hemorrhage in rats. Journal 
 Therapeutic Hypothermia in Brain Injury 68 
of Stroke and Cerebrovascular Diseases: The Official Journal of National Stroke 
Association. [10.1016/j.jstrokecerebrovasdis.2008.01.003]. 2008;17(4):187-95. 
[69] Howell DA, Posnikoff J, Stratford JG. Prolonged hypothermia in treatment of massive 
cerebral haemorrhage; a preliminary report. Canadian Medical Association Journal. 
1956;75(5):388-94. 
[70] Kollmar R, Juettler E, Huttner HB, D√∂rfler A, Staykov D, Kallmuenzer B, et al. Cooling 
in intracerebral hemorrhage (CINCH) trial: protocol of a randomized German-Austrian 
clinical trial. International Journal of Stroke: Official Journal of the International Stroke 
Society. [10.1111/j.1747-4949.2011.00707.x]. 2012;7(2):168-72. 
[71] Gasser S, Khan N, Yonekawa Y, Imhof HG, Keller E. Long-term hypothermia in 
patients with severe brain edema after poor-grade subarachnoid hemorrhage: feasibility 
and intensive care complications. J Neurosurg Anesthesiol. 2003 Jul;15(3):240-8. 
[72] Krieger DW, Georgia D, A M, Abou-Chebl A, Andrefsky JC, Sila CA, et al. Cooling for 
Acute Ischemic Brain Damage (COOL AID) An Open Pilot Study of Induced 
Hypothermia in Acute Ischemic Stroke. Stroke. [10.1161/01.STR.32.8.1847]. 
2001;32(8):1847-54. 
[73] Ginsberg MD, Sternau LL, Globus MY, Dietrich WD, Busto R. Therapeutic modulation 
of brain temperature: relevance to ischemic brain injury. Cerebrovascular and Brain 
Metabolism Reviews. 1992;4(3):189-225. 
[74] Krieger DW, Yenari MA. Therapeutic hypothermia for acute ischemic stroke: what do 
laboratory studies teach us? Stroke. 2004 Jun;35(6):1482-9. 
[75] Steiner T, Friede T, Aschoff A, Schellinger PD, Schwab S, Hacke W. Effect and 
feasibility of controlled rewarming after moderate hypothermia in stroke patients with 
malignant infarction of the middle cerebral artery. Stroke. 2001 Dec 1;32(12):2833-5. 
[76] Samaniego EA, Mlynash M, Caulfield AF, Eyngorn I, Wijman CAC. Sedation confounds 
outcome prediction in cardiac arrest survivors treated with hypothermia. Neurocritical 
Care. [10.1007/s12028-010-9412-8]. 2011;15(1):113-9. 
[77] Samaniego EA, Persoon S, Wijman CAC. Prognosis after cardiac arrest and 
hypothermia: a new paradigm. Current Neurology and Neuroscience Reports. 
[10.1007/s11910-010-0148-9]. 2011;11(1):111-9. 
[78] Den Hertog HM, van der Worp HB, Tseng MC, Dippel DW. Cooling therapy for acute 
stroke. Cochrane Database Syst Rev. 2009(1):CD001247. 
[79] Gillies MA, Pratt R, Whiteley C, Borg J, Beale RJ, Tibby SM. Therapeutic hypothermia 
after cardiac arrest: a retrospective comparison of surface and endovascular cooling 
techniques. Resuscitation. [10.1016/j.resuscitation.2010.05.001]. 2010;81(9):1117-22. 
[80] Finley Caulfield A, Rachabattula S, Eyngorn I, Hamilton SA, Kalimuthu R, Hsia AW, et 
al. A Comparison of Cooling Techniques to Treat Cardiac Arrest Patients with 
Hypothermia. Stroke Research and Treatment. [10.4061/2011/690506]. 2011;2011:1-6. 
[81] Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated 
view. Trends Neurosci. 1999 Sep;22(9):391-7. 
[82] Krieger DW, Yenari MA. Therapeutic hypothermia for acute ischemic stroke: what do 
laboratory studies teach us? Stroke; a Journal of Cerebral Circulation. 
[10.1161/01.STR.0000126118.44249.5c]. 2004;35(6):1482-9. 
